Expert Interview
Getting a prescriber's perspective comparing Briumvi, Ocrevus and Kesimpta in treating multiple sclerosis
Ticker(s): TGTX, RHHBY, NVSInstitution: The Boster Center for Multiple Sclerosis
- Founder, The Boster Center for Multiple Sclerosis.
- Manages 1400 patients with Multiple Sclerosis and has prescribed Ocrevus, Kesimpta and Briumvi.
- Principal investigator in numerous Clinical Trials and published extensively in medical journals.
How many patients with MS do you currently manage
Added By: dami_adminHow many patients do you currently have on the following treatments:
- Ocreveus
- Briumvi
- Kasimpta
On a scale from 1-10 (10 being extremely excited), how would you rate your level of excitement for each drug?
Added By: dami_adminAre You Interested In These Questions?
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
